Effect of live and inactivated probiotic strains of <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> on myocardial infarction size in rats with systemic inflammatory response syndrome
-
Published:2024-06-28
Issue:1
Volume:110
Page:94-107
-
ISSN:2658-655X
-
Container-title:Российский физиологический журнал им И М Сеченова
-
language:
-
Short-container-title:Rossijskij fiziologičeskij žurnal im. I.M. Sečenova
Author:
Borshchev Y. Y.12, Sonin D. L.13, Burovenko I. Y.1, Protsak E. S.1, Borshchev V. Y.3, Borshcheva O. V.1, Galagudza M. M.13
Affiliation:
1. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation 2. National Medical Research Center of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation 3. Pavlov First St. Petersburg State Medical University
Abstract
Within the concept of a heart-gut axis, new works are emerging to support the efficacy of probiotic strains to increase myocardial resistance to ischemia-reperfusion injury (IRI) in comorbidity. The question remains open whether the presence of live probiotic bacteria is a necessary condition for the realization of their cardioprotective effect. The aim of this work was to determine the manifestation of cardio-protective effect of living and pasteurized probiotic strains Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12) in rats with systemic inflammatory response syndrome (SIRS). Myocardial resistance to IRI was assessed using an in vivo model of left coronary artery occlusion-reperfusion. Experiments were performed on male Wistar rats with improved conventional status with visceral obesity, chemically induced colitis and antibiotic-induced dysbiosis, which together provided the formation of (SIRS) against the background of oral administration of live and inactivated probiotic bacteria. Myocardial resistance to ischemia-reperfusion injury was assessed using the technique of left coronary artery occlusion in vivo. The infarct size in the group with simulated SIRS was significantly higher than in the control group 43% (39; 44) and 31% (28; 35), (p 0.05). In the SIRS group with the introduction of inactivated probiotic bacteria, the infarct size 45% (37; 48) did not differ from the SIRS group and was significantly higher than in the control (p 0.05). At the same time, the size of the infarction in the group with the introduction of live probiotics did not differ from that in the control group and amounted to 32% (28; 37). There are specific features of the action of live and inactivated probiotic microorganisms with preservation of cardioprotective effect when using live lacto- and bifidobacteria in animals with SIRS.
Publisher
The Russian Academy of Sciences
Reference31 articles.
1. Шляхто ЕВ, Петрищев НН, Галагудза ММ, Власов ТД, Нифонтов ЕМ (2013). Кардиопротекция: фундаментальные и клинические аспекты. CПб. ООО Студия “НП-Принт”. [Shlyakhto EV, Petrishchev NN, Galagudza MM, Vlasov TD, Nifontov EM (2013) Cardioprotection: fundamental and clinical aspects. SPb. OOO Studiya “NP-Print”. (In Russ)]. 2. Heusch G (2017) Critical Issues for the Translation of Cardioprotection. Circul Res 120(9): 1477–1486. https://doi.org/10.1161/CIRCRESAHA.117.310820 3. Wang Q, Zuurbier CJ, Huhn R, Torregroza C, Hollmann MW, Preckel B, van den Brom CE, Weber NC (2023) Pharmacological Cardioprotection against Ischemia Reperfusion Injury-The Search for a Clinical Effective Therapy. Cells 12(10): 1432. https://doi.org/10.3390/cells12101432 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V (2020) GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 76(25): 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010 5. Kundu P, Blacher E, Elinav E, Pettersson S (2017) Our Gut Microbiome: The Evolving Inner Self. Cell 171(7): 1481–1493. https://doi.org/10.1016/j.cell.2017.11.024
|
|